PMID: 3755857Aug 1, 1986Paper

The development of thyrotoxicosis (Graves' disease) during immunosuppression for autoimmune haemolytic anaemia

Acta Endocrinologica
J A ThomsonI D Walker

Abstract

A patient is described who developed thyrotoxicosis (Graves' disease) during immunosuppressive therapy for acquired autoimmune haemolytic anaemia. The fact that the two conditions may be associated should be recognised. Long-term immunosuppressive therapy does not prevent the development of immunoglobulins of IgG type postulated to be aetiologically involved in Graves' disease.

Citations

Jul 12, 2005·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Israel B OrijaRobert S Zimmerman
Jun 18, 2003·Journal of Endocrinological Investigation·T BednarczukJ Nauman
Oct 1, 1987·Journal of Endocrinological Investigation·R Candrina, G Giustina

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.